[{"address1": "41 South Rio Grande Street", "city": "Salt Lake City", "state": "UT", "zip": "84101", "country": "United States", "phone": "385 269 0203", "fax": "801 821 2872", "website": "https://www.recursion.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.", "fullTimeEmployees": 500, "companyOfficers": [{"maxAge": 1, "name": "Dr. Christopher C. Gibson Ph.D.", "age": 41, "title": "Co-Founder, CEO & Director", "yearBorn": 1983, "fiscalYear": 2023, "totalPay": 806716, "exercisedValue": 2177540, "unexercisedValue": 222044}, {"maxAge": 1, "name": "Dr. Dean Y. Li M.D., Ph.D.", "age": 60, "title": "Co-Founder & Independent Director", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 47505, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Blake C. Borgeson Ph.D.", "age": 42, "title": "Co-Founder & Director", "yearBorn": 1982, "fiscalYear": 2023, "totalPay": 40000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David J. Mauro M.D., Ph.D.", "age": 59, "title": "Chief Medical Officer", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 674737, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ben R. Taylor", "age": 47, "title": "CFO & President of Recursion UK", "yearBorn": 1977, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kristen  Rushton M.B.A.", "title": "Chief Operating Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Kevin  Leggat", "title": "Vice President of Finance & Accounting", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Benjamin  Mabey M.S.", "age": 41, "title": "Chief Technology Officer", "yearBorn": 1983, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David  Hallett Ph.D.", "age": 55, "title": "Chief Scientific Officer", "yearBorn": 1969, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jared  Allenbach", "title": "Senior Director of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 7, "compensationRisk": 9, "shareHolderRightsRisk": 10, "overallRisk": 9, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 10.35, "open": 10.38, "dayLow": 9.17, "dayHigh": 10.6, "regularMarketPreviousClose": 10.35, "regularMarketOpen": 10.38, "regularMarketDayLow": 9.17, "regularMarketDayHigh": 10.6, "payoutRatio": 0.0, "beta": 0.859, "forwardPE": -5.317919, "volume": 28211070, "regularMarketVolume": 28211070, "averageVolume": 21521176, "averageVolume10days": 44780430, "averageDailyVolume10Day": 44780430, "bid": 7.47, "ask": 11.87, "bidSize": 2, "askSize": 2, "marketCap": 3594642176, "fiftyTwoWeekLow": 5.6, "fiftyTwoWeekHigh": 15.74, "priceToSalesTrailing12Months": 55.14608, "fiftyDayAverage": 7.5155, "twoHundredDayAverage": 7.473825, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 2631753728, "profitMargins": 0.0, "floatShares": 272800373, "sharesOutstanding": 383724000, "sharesShort": 63748978, "sharesShortPriorMonth": 73735739, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.16319999, "heldPercentInsiders": 0.037219997, "heldPercentInstitutions": 0.79240996, "shortRatio": 3.77, "shortPercentOfFloat": 0.17790002, "impliedSharesOutstanding": 390721984, "bookValue": 1.833, "priceToBook": 5.0190945, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -377751008, "trailingEps": -1.54, "forwardEps": -1.73, "enterpriseToRevenue": 40.374, "enterpriseToEbitda": -7.227, "52WeekChange": -0.22587883, "SandP52WeekChange": 0.2021538, "quoteType": "EQUITY", "currentPrice": 9.2, "targetHighPrice": 11.0, "targetLowPrice": 6.0, "targetMeanPrice": 9.14286, "targetMedianPrice": 10.0, "recommendationMean": 2.625, "recommendationKey": "hold", "numberOfAnalystOpinions": 7, "totalCash": 427647008, "totalCashPerShare": 1.491, "ebitda": -364150016, "totalDebt": 90625000, "quickRatio": 3.948, "currentRatio": 4.355, "totalRevenue": 65184000, "debtToEquity": 17.276, "revenuePerShare": 0.265, "returnOnAssets": -0.36398998, "returnOnEquity": -0.78492, "grossProfits": -262710000, "freeCashflow": -198302368, "operatingCashflow": -317820992, "revenueGrowth": 1.476, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -3.77095, "financialCurrency": "USD", "symbol": "RXRX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "REGULAR", "shortName": "Recursion Pharmaceuticals, Inc.", "longName": "Recursion Pharmaceuticals, Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1618579800000, "corporateActions": [], "regularMarketTime": 1740170811, "exchange": "NMS", "messageBoardId": "finmb_261401243", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChange": -1.1500006, "regularMarketDayRange": "9.17 - 10.6", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 21521176, "fiftyTwoWeekLowChange": 3.6, "fiftyTwoWeekLowChangePercent": 0.64285713, "fiftyTwoWeekRange": "5.6 - 15.74", "fiftyTwoWeekHighChange": -6.54, "fiftyTwoWeekHighChangePercent": -0.41550192, "fiftyTwoWeekChangePercent": -22.587883, "earningsTimestampStart": 1740481140, "earningsTimestampEnd": 1741003200, "earningsCallTimestampStart": 1723120200, "earningsCallTimestampEnd": 1723120200, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.54, "epsForward": -1.73, "epsCurrentYear": -1.54133, "priceEpsCurrentYear": -5.968871, "fiftyDayAverageChange": 1.6844997, "fiftyDayAverageChangePercent": 0.22413674, "twoHundredDayAverageChange": 1.7261748, "twoHundredDayAverageChangePercent": 0.23096271, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-04-16", "averageAnalystRating": "2.6 - Hold", "cryptoTradeable": false, "regularMarketChangePercent": -11.111116, "regularMarketPrice": 9.2, "displayName": "Recursion Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2025-02-21"}]